HOME >> MEDICINE >> NEWS
Estrogen shows potential as stroke treatment, UF animal studies show

GAINESVILLE, Fla.---A high dose of estrogen administered soon after a stroke can prevent a substantial amount of brain damage in laboratory animals, University of Florida researchers reported today (3/3) in the American Heart Association journal Stroke.

When rats are injected with the female hormone within 30 minutes of a surgically induced stroke, the death rate for brain cells drops by 60 percent. Even three hours later, estrogen still can save 30 to 40 percent of the cells, said James W. Simpkins, chairman of the department of pharmaceutics in UF's College of Pharmacy and director of the university's Center for the Neurobiology of Aging.

The study builds on statistical observations that postmenopausal women who take estrogen replacement therapy are more likely to survive stroke than those who do not.

Simpkins, who has been studying estrogen for 25 years, noted that in previous laboratory studies, he and his colleagues have shown that giving the hormone before a stroke can protect against its harmful effects.

"Here we have confirmation that it has potential for treating a patient who comes into the emergency room with stroke symptoms," said Simpkins, who also is affiliated with UF's Brain Institute and collaborated on the research with UF neurosurgeons Shao-Hua Yang and Arthur Day.

Simpkins cautioned, however, that much more research needs to be done before anyone afflicted with stroke is treated with estrogen. Clinical trials will have to be conducted to test the safety and effectiveness of such an approach in humans, he said.

An estimated 500,000 Americans suffer stroke each year, according to the National Institutes of Health, with approximately 80 percent of the attacks resulting from a clot that blocks the flow of blood to an area of the brain. Without oxygen and essential nutrients, brain cells begin to die. The more severe the die-off, the more pronounced the resulting physical and cognitive limitations, such as paralysis or d
'"/>

Contact: Victoria White
vickiwhite@xtalwind.net
352-344-2738
University of Florida
1-Mar-2000


Page: 1 2 3

Related medicine news :

1. Estrogen-associated COX-2 pathways explain protection from heart disease in female mice
2. Estrogen or stimulating environment boost memory
3. Estrogenlike drugs may eventually help postmenopausal women with weight gain
4. Estrogen offers no overall benefit for disease prevention in postmenopausal women with hysterectomy
5. Estrogen makes the brain more vulnerable to stress
6. Estrogen replacement increases risk factors for arrhythmia and sudden death
7. Estrogen may lower womens risk of heart disease by working as damper on inflammation
8. Estrogen may dictate what problem-solving strategy brain uses
9. Testosterone may reduce risk of stroke in men; Estrogen levels not related to stroke
10. Estrogens role in preventing female cardiac disease
11. Estrogen has antitumor activity in hormone therapy-resistant breast tumors

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Estrogen shows potential stroke treatment animal studies show

(Date:5/21/2013)... York (PRWEB) May 21, 2013 The ... Conserve hip replacement lawsuits in U.S. District ... in response to a request from Plaintiffs’ Counsel to ... Defendant. The May 17th Order grants that request, ... be conducted. (In re: Wright Medical Technology, Inc., Conserve ...
(Date:5/21/2013)... MedMar Healing Center announces their participation ... Food Bank. Twenty-eight businesses, including MedMar Healing Center, doctors, and ... The goal is to raise food to help area kids ... families in recent years. , “We like being able ... need,” explains Douglas Chloupek of MedMar Healing Center. “Taking part ...
(Date:5/21/2013)... Defense Serum Repository (DoDSR), University of Cincinnati (UC) researchers ... disease (IBD), which could help with earlier diagnosis and ... , This finding, the first of its kind and ... via podium presentation by staff from Walter Reed National ... held May 18-21 in Orlando, Fla. , The ...
(Date:5/21/2013)... 21, 2013 Today, Zane Benefits, Inc. ... FSA accounts. Zane Benefits, which provides comprehensive and ... the leader in defined contribution and ... , According to Zane Benefits’ website, the Affordable Care ... into law in 2010 and impacts many areas of ...
(Date:5/21/2013)... May 21, 2013 The American Diabetes ... people in the United States of America are affected ... at a great risk of developing peripheral neuropathy which ... lives. The ADA further goes on saying that the ... and around 2 million new cases are diagnosed every ...
Breaking Medicine News(10 mins):Health News:Wright Hip Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Order in Federal Wright Conserve Hip Replacement Litigation 2Health News:Wright Hip Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Order in Federal Wright Conserve Hip Replacement Litigation 3Health News:San Jose Cannabis Club Helps Feed Hungry Children with Second Harvest Food Bank 2Health News:Biomarkers discovered for inflammatory bowel disease 2Health News:Zane Benefits Publishes New Information on HRA, HSA and FSA Accounts 2Health News:Zane Benefits Publishes New Information on HRA, HSA and FSA Accounts 3Health News:Neuracel Aims to Reduce Peripheral Neuropathy Pain 2
(Date:5/21/2013)... N.Y. , May 21, 2013 Sanofi ... (NASDAQ: REGN) today announced that the New England ... 2a study results of dupilumab (SAR231893/REGN668) in patients with ... targeting the alpha subunit of the interleukin 4 receptor ... IL-13, drivers of Th2 (Type 2 helper T cell) ...
(Date:5/21/2013)... May 21, 2013 U.S. spending on specialty ... diseases such as cancer, multiple sclerosis and rheumatoid arthritis ... end of 2015, according to a forecast released today ... http://photos.prnewswire.com/prnh/20080827/EXPRESSSCRIPTSLOGO ) "As we see ... health plans to act so they can continue to ...
(Date:5/21/2013)... CITY, Calif. , May 21, 2013 ... ACRX ), a specialty pharmaceutical company focused ... therapies for the treatment of acute and ... that in a placebo-controlled Phase 3 study ... (patient-controlled analgesia) System (NanoTab System), the primary ...
Breaking Medicine Technology:Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 2Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 3Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 4Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 5Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 6Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 7U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 2U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 3U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 4U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 5Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 2Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 3Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 4Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 5Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 6Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 7Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 8Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 9Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 10
Cached News: